Epigenetics diagnostics market seen reaching $35.17 billion by 2030

The Business Research Company says the epigenetics diagnostics market is set to grow from $16.56 billion in 2025 to $35.17 billion by 2030, powered by personalized medicine, sequencing advances and expanding clinical research. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - The epigenetics diagnostics market sits at the center of precision medicine, where gene activity markers can help guide prevention, diagnosis and treatment. - Rising demand for personalized care is widening the use case for tools that detect DNA methylation, histone changes and other epigenetic signals. - The market’s projected growth points to stronger demand from oncology, metabolic disease and pharma research.

What happened: - The Business Research Company projected the epigenetics diagnostics market will rise from $16.56 billion in 2025 to $19.29 billion in 2026. - The report forecasts the market will reach $35.17 billion by 2030, implying a 16.2% CAGR from 2026 through 2030. - The company also said historical growth had been limited by scarce dedicated epigenetic tools, reliance on traditional molecular biology techniques and slow adoption of automation. - The report was published in London on August 6, 2026. - Download a free sample of the report. - View the full market report.

The details: - Epigenetic diagnostics studies molecular changes that regulate gene expression without altering the DNA sequence. - Key markers include DNA methylation and histone alterations. - The report points to sequencing innovation, epigenetic analysis methods and cloud-based bioinformatics as major growth drivers. - Rising investment in personalized medicine is also expected to support demand. - Additional growth drivers include diagnostics for oncology and metabolic diseases, plus higher demand from pharmaceutical and biotechnology companies. - The market is seeing broader use of epigenetic biomarker kits, next-generation sequencing, microarray platforms, data analytics and bioinformatics tools, automated liquid handling systems and high-throughput technologies. - The report breaks the market into Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region through the forecast period.

Between the lines: - The market forecast reflects a broader shift from one-size-fits-all care toward treatments shaped by molecular profiling. - FDA approvals for personalized therapies can feed demand for diagnostics that help identify which patients are most likely to respond. - The report’s emphasis on automation and bioinformatics suggests the market is moving from niche research use toward more scalable clinical and commercial workflows.

What's next: - The Business Research Company expects continued gains as sequencing platforms, biomarker kits and automated systems become more widely adopted. - Growing healthcare spending and clinical research activity in Asia-Pacific could narrow the gap with North America over time. - Pharmaceutical and biotechnology buyers are likely to remain an important demand source as personalized medicine expands.

The bottom line: - Epigenetics diagnostics is moving from a research-heavy category to a faster-growing commercial market, with personalized medicine acting as the main tailwind.